This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Abbott-Exact Sciences deal cleared by Australian antitrust regulator

( February 24, 2026, 06:23 GMT | Official Statement) -- MLex Summary: Global healthcare company Abbott Laboratories’ proposal to acquire Exact Sciences has been approved as the Australian competition regulator said the deal is unlikely to have the effect of substantially lessening competition in any market. In a determination published on Tuesday, the Australian Competition & Consumer Commission said there is limited horizontal overlap between the Abbott Laboratories and Exact Sciences. The determination said that while the two companies operate in the oncology diagnostic sector, their products are functionally different and are not substitutes.Determination is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections